XENON PHARMACEUTICALS INC. Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31)
XENON PHARMACEUTICALS INC. (XENE) reported Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) of -$175.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-09.
Discontinued › Notes › Equity
us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1 · last filed 2020-05-26
- XENON PHARMACEUTICALS INC. cumulative effect on retained earnings, net of tax (deprecated 2020-01-31) for the quarter ending 2019-03-31 was -$175.00K.
- XENON PHARMACEUTICALS INC. cumulative effect on retained earnings, net of tax (deprecated 2020-01-31) for fiscal 2019 was -$175.00K.
| Period end | Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) 3 month | Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) 12 month |
|---|---|---|
| 2019-12-31 | -$175.00K 10-K · filed 2020-03-09 | |
| 2019-03-31 | -$175.00K 10-Q/A · filed 2020-05-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |